Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
14
self-reported 11–50 band
Founded
2016
10 years
Legal entities
1
ABR
Office countries
1
2 addresses
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
RACURA ONCOLOGY LTD
ABN61149318749
Legal entities
Show as table · Racura Oncology: 1 registry entity
| RACURA ONCOLOGY LTD | ABN 61149318749 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|
All codes: AU
Addresses
- AUWollongong , NSW
- AU1 Macquarie Place; Level 36; Sydney, NSW 2000Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Racura Oncology?
One New South Wales entity on the ABR. RACURA ONCOLOGY LTD (ABN 61 149 318 749), high confidence.
How many people work at Racura Oncology?
The record holds 14 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Racura Oncology have offices?
Two addresses on record, Australia only. Primary: 1 Macquarie Place, Level 36, Sydney, NSW 2000.
Has Racura Oncology raised funding?
None linked to this brand.
What does Racura Oncology list as its specialties?
Seven tags on the brand's own list, among them aml.
Which companies are listed alongside Racura Oncology?
6 profiles list Racura Oncology as a peer — 75th percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. BioNSW lists it back.